A Study to Evaluate Valbenazine for Tardive Dyskinesia
Phase 4
50
about 1.7 years
18+
19 sites in AR, CA, FL +5
About this study
Researchers are testing whether valbenazine helps people with tardive dyskinesia who are still experiencing symptoms, even after stopping a VMAT2 inhibitor. The trial will last 609 days and involve approximately 50 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Valbenazine
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
valbenazine
oral (Oral Capsule)
Primary: Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24
Secondary: Change from Baseline in the Clinical Global Impression of Severity - Tardive Dyskinesia (CGI-TD-S) Score at Week 24, Change from Baseline in the EuroQol-Visual Analogue Scale (EQ-VAS) at Week 24, Change from Baseline in the Tardive Dyskinesia Impact Scale (TDIS) at Week 24
Psychiatry / Mental Health